<DOC>
	<DOCNO>NCT01256398</DOCNO>
	<brief_summary>This phase II clinical trial study well dasatinib follow stem cell transplant work treat old patient newly diagnose acute lymphoblastic leukemia . Dasatinib may stop growth cancer cell block enzymes need cell growth . Giving chemotherapy stem cell transplant stop growth cancer cell stop divide kill . Monoclonal antibody , alemtuzumab , may interfere ability cancer cell grow spread . Giving one drug ( combination chemotherapy ) give dasatinib together chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Dasatinib Followed Stem Cell Transplant Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate disease-free survival ( DFS ) overall survival ( OS ) profile newly diagnose patient 18 year old Philadelphia chromosome positive ( Ph+ ) ( BCR/ ( v-abl Abelson murine leukemia viral oncogene homolog [ ABL ] + ) acute lymphoblastic leukemia ( ALL ) receive sequential dasatinib follow allogeneic autologous hematopoietic cell transplant ( HCT ) chemotherapy follow dasatinib maintenance . SECONDARY OBJECTIVES : I . Compare OS DFS profile three cohort similar population study . II . Determine ability dasatinib produce maintain BCR/ABL-negative status , judge quantitative-polymerase chain reaction ( Q-PCR ) follow sequential dasatinib , chemotherapy , HCT . III . Determine feasibility collect adequate peripheral blood stem cell autologous HCT follow dasatinib therapy ass residual Ph+ ( BCR/ABL+ ) cell Q-PCR . IV . Study safety efficacy autologous HCT follow therapy dasatinib . V. Study safety efficacy reduced-intensity preparatory regimen follow allogeneic HCT follow induction therapy dasatinib . VI . Study safety efficacy dasatinib maintenance administer allogeneic autologous HCT chemotherapy . VII . Correlate plasma cerebrospinal fluid ( CSF ) level dasatinib give orally induction . OUTLINE : As 8/21/2014 , new patient may enrol E3903 . REMISSION INDUCTION THERAPY ( RIT ) : Patients receive dasatinib orally ( PO ) daily continuously dexamethasone PO intravenously ( IV ) day 1-7 . EARLY INTENSIFICATION THERAPY : Patients bone marrow = &lt; 20 % blast assign cohort A patient bone marrow &gt; 20 % blast assign cohort B. COHORT A : Patients receive dasatinib dexamethasone RIT . COHORT B : Patients receive dasatinib dexamethasone RIT , vincristine sulfate IV daunorubicin hydrochloride IV day 1 , 8 , 15 . Patients NOT achieve complete response ( CR ) CR incomplete hematologic recovery base bone marrow continue second induction therapy ; patient achieve hematologic morphologic CR continue CNS prophylaxis therapy . SECOND INDUCTION THERAPY : Patients receive dasatinib dexamethasone RIT , cyclophosphamide IV day 1 , daunorubicin hydrochloride IV vincristine sulfate IV day 1 8 , filgrastim subcutaneously ( SC ) begin day 9 continue &gt; = 7 day one dose pegfilgrastim day 9 . CNS PROPHYLAXIS THERAPY : Patients receive dasatinib PO daily continuously CNS prophylaxis therapy ; methotrexate intrathecally ( IT ) , vincristine sulfate IV , methotrexate IV 3 hour day 1 , 15 , 29 ; methotrexate PO every 6 hour total 4 dos day 1-2 , 15-16 , 29-30 ; leucovorin calcium IV day 2 , 16 , 30 ; leucovorin PO calcium every 6 hour total 8 dos day 3-4 , 17-18 , 31-32 . TRANSPLANTATION OR ALTERNATIVE CHEMOTHERAPY AND MAINTENANCE THERAPY : Patients age 50-70 year HLA-matched relate unrelated donor assign allogeneic transplantation , patient age 50-70 year without HLA-matched related unrelated donor assign autologous transplantation , patient age &gt; 70 year transplantation candidate assign alternative chemotherapy . ALLOGENEIC TRANSPLANTATION : Patients receive fludarabine phosphate IV 30 minute alemtuzumab IV 30 minute day -7 -3 melphalan IV 30 minute day -2 . Patients undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . Patients receive filgrastim SC begin day 1 continue count recovery tacrolimus IV PO begin day -2 begin taper day 100 ( match relate donor ) day 180 ( mismatch relate unrelated donor ) . Beginning day 30 , patient receive dasatinib PO daily maintenance therapy . Treatment continue &gt; = 12 month absence disease progression . AUTOLOGOUS TRANSPLANTATION : MOBILIZATION : Patients receive etoposide phosphate IV continuously day 1-4 , high-dose cytarabine IV 2 hour every 12 hour total 8 dos day 1-4 , filgrastim SC twice daily begin day 14 continue peripheral blood stem cell collection complete WBC &gt; 50,000/μL . LEUKAPHERESIS : Patients undergo leukapheresis begin WBC &gt; 10,000/μL target collection &gt; = 5 x 10^6 CD34+ cells/kg . After completion stem cell collection , patient receive dasatinib PO twice daily 3 day transplantation . TRANSPLANTATION : Beginning &gt; = 4 week recovery toxicity relate previous treatment , patient receive melphalan IV 30 minute day -2 -1 . Patients undergo autologous PBSCT day 0 . Patients receive filgrastim SC begin day 0 continue count recovery . MAINTENANCE THERAPY : Beginning day 30 , patient receive dasatinib PO daily . Treatment continue &gt; = 12 month absence disease progression . ALTERNATIVE CHEMOTHERAPY : Beginning 3-10 day completion CNS prophylaxis therapy , patient receive etoposide phosphate IV continuously day 1-4 , high-dose cytarabine IV 2 hour every 12 hour total 8 dos day 1-4 , filgrastim SC twice daily begin day 14 continue count recovery . MAINTENANCE THERAPY : Patients receive dasatinib PO daily begin day 30 . Patients also receive vincristine sulfate IV every 4 week , dexamethasone 5 day every 4 week , mercaptopurine PO daily , methotrexate PO weekly . Treatment continue &gt; = 12 month absence disease progression . NOTE : Patients CNS leukemia testicular disease may receive additional treatment . After completion study treatment , patient follow every month 1 year , every 3 month 2 year , every 6 month 2 year , every year 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Unequivocal histologic diagnosis ALL Detection ( 9 ; 22 ) ( q34 ; q11 ) 3way variant metaphase cytogenetics BCRABL positive status molecular analysis ( QPCR fluorescent situ hybridization [ FISH ] ) Cruise Lines International Association ( CLIA ) approve laboratory No prior therapy except one week corticosteroid and/or hydroxyurea enable time detection ( 9 ; 22 ) ( q34 ; q11 ) BCR/ABL Nonpregnant nonnursing ; treatment protocol would expose unborn child significant risk ; woman men reproductive potential agree use effective mean birth control contraception continue three month last dose dasatinib allow complete clearance drug principal metabolite body ; woman childbearing potential , pregnancy test require study entry Left ventricular ejection fraction &gt; = low limit institutional normal No myocardial infarction within 6 month No ventricular tachyarrhythmia within 6 month No major conduction abnormality ( unless cardiac pacemaker present )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>